Inventor
Ravindra Kumar
Inventor
Acton, MA, US
Overview
Patents· 91 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations25%
C07KPeptides24%
A61KPreparations for medical, dental or toiletry purposes22%
C12NMicroorganisms or enzymes11%
C12YEnzymes4%
G06FElectric digital data processing3%
C07HSugars3%
G01NInvestigating or analysing materials by determining their chemical or physical properties2%
H04LTransmission of digital information, e.g. telegraphic communication2%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms1%
PatentTitleYear
10,829,533Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels202010,829,534Methods and compositions for increasing red blood cells202010,829,532Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels202010,765,626Methods for treatment of charcot-marie-tooth disease with follistatin polypeptides202010,745,462Methods of treating a sclerotic disorder by administering a transforming growth factor beta receptor type II fusion polypeptide202010,738,098ALK4:ActRIIB heteromultimers and uses thereof202010,722,558Compositions and methods for treating pulmonary hypertension202010,695,405Compositions and methods for treating pulmonary hypertension202010,689,427Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels202010,682,392Methods for treating pulmonary hypertension with a TGF-beta type II receptor-FC fusion protein202010,603,359Methods and compositions using GDF15 polypeptides for increasing red blood cells202010,501,547ALK7 binding proteins and uses thereof201910,487,347Method of pretreatment for enhanced enzymatic hydrolysis201910,377,996Methods of identifying ActRIIB variants201910,358,476Single arm type I and type II receptor fusion proteins and uses thereof201910,358,633Method for producing an ActRIIB-Fc fusion polypeptide201910,344,066Methods and compositions for increasing red blood cells201910,316,076Transforming growth factor-beta receptor type II fusion polypeptides201910,307,455Activin type 2 receptor antibodies201910,259,861Variants derived from ActRIIB and uses therefor201910,227,393TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof201910,227,392ALK7:ActRIIB heteromultimers and uses thereof201910,196,434ALK4:ActRIIB heteromultimers and uses thereof201910,176,286System, method, and computer program product for oscillating loop detection in formal verification201910,131,700Methods for treating refractory anemia with ringed sideroblasts201810,059,756Compositions comprising ALK1-ECD protein201810,023,621Follistatin-related fusion proteins201810,010,498Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins20189,975,934Follistatin-related fusion proteins20189,932,386Endoglin polypeptides and uses thereof20189,932,379Isolated nucleotide sequences encoding GDF traps20189,884,900'Methods for treating Janus kinase-associated disorders by administering soluble transforming growth factor beta type II receptor'20189,809,636'Methods for increasing red blood cell levels comprising administering BMP9'20179,809,637'Transforming growth factor beta receptor II fusion polypeptides'20179,790,284'Methods for increasing thermogenic adipocytes'20179,745,559'Method for decreasing the body fat content in a subject by administering an ActRIIB protein'20179,624,301'Polynucleotides encoding an actriib antibody'20179,572,865'Activin-actriia antagonists and uses for treating multiple myeloma'20179,569,375'Unifying class device interface with one host interface by using embedded controller'20179,526,759'Activin-actriia antagonists and uses for treating or preventing breast cancer'20169,505,813'Use of GDF traps to treat anemia'20169,452,197'Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof'20169,439,945'Isolated nucleotide sequences encoding GDF traps'20169,403,910'Polynucleotides encoding an actriib antibody'20169,399,669'Variants derived from ActRIIB'20169,348,730'Firmware ROM patch method'20169,181,533'Truncated ACTRIIB-FC fusion protein'20158,883,982'Compositions and methods for increasing serum half-life'20148,796,199'Uses of Cerberus and derivatives thereof'20148,765,385'Method of detection of neutralizing anti-actriib antibodies'20148,765,663'Methods for increasing adiponectin'20148,722,615'Compositions and methods for increasing serum half-life'20148,703,927'Isolated nucleotide sequences encoding GDF traps'20148,703,694'Methods for increasing thermogenic adipocytes'20148,642,031'Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof'20148,455,428'ALK1 receptor and ligand antagonist and uses thereof'20138,361,957'Isolated GDF trap polypeptide'20138,353,972'Synthetic fuel and method of preparation thereof'20138,343,933'Variants derived from ActRIIB and uses therefor'20138,346,952'De-centralization of group administration authority within a network storage architecture'20138,293,881'Isolated nucleic acid encoding a truncated ActRIIB fusion protein'20128,271,556'Method and system for managing clustered and non-clustered storage systems'20128,232,252'P-selectin ligand protein'20128,216,997'Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators'20128,178,488'Methods for increasing thermogenic adipocytes'20128,173,601'Activin-ActRIIa antagonists and uses for treating multiple myeloma'20128,158,584'Pharmaceutical preparations comprising an ALK1-Fc fusion protein'20128,138,142'Methods for increasing adiponectin in a patient in need thereof'20128,135,676'Method and system for managing data in storage systems'20128,058,229'Method of increasing red blood cell levels or treating anemia in a patient'20118,055,380'Daily pill dispensing apparatus'20118,051,113'Method and system for managing clustered and non-clustered storage systems'20117,927,835'Nucleic acids encoding P-selectin ligand fusion proteins'20117,926,049'System and method for determining differences between software configurations'20117,842,663'Variants derived from ActRIIB and uses therefor'20107,833,971'Uses of cerberus, coco and derivatives thereof'2010D0619351'Pill organizer and dispenser'20107,727,535'Platelet glycoprotein Ib alpha variant fusion polypeptides and methods of use thereof'20107,612,040'Lefty polypeptides and derivatives thereof'20097,563,760'P-selectin ligand protein'20097,565,519'System and method for automatically upgrading/reverting configurations across a plurality of product release lines'20097,049,128'Platelet glycoprotein Ibα fusion polypeptides and methods of use thereof'20066,991,796'Platlet glycoprotein IBα fusion polypeptides and methods of use thereof'20066,861,055'Human GDP-mannose 4,6-dehydratase'20056,277,975'Fusions of P-selectin ligand protein and polynucleotides encoding same'20015,942,228'Human GDP-mannose 4,6 dehydratase'19995,869,307'Human GDP-mannose 4,6-dehydratase'19995,843,707'Nucleic acid encoding a novel P-selectin ligand protein'19985,840,679'Method of inhibiting P-selectin ligand activity'19985,827,817'P-selectin ligand protein'19985,728,568'Human GDP-mannose 4,6 dehydratase'1998Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1998–2001Patents assigned to GENETICS INST (7)· patent assignee history
1998–2012Based in Belmont, MA, US· patent location history
2006–2020Based in Acton, MA, US· patent location history
2009–2020Patents assigned to ACCELERON PHARMA INC (61)· patent assignee history
2009–2013Based in Bangalore, IN· patent location history
2010–2018Patents assigned to KUMAR RAVINDRA (30)· patent assignee history
2010–2011Based in Houston, TX, US· patent location history
2011–2018Patents assigned to SEEHRA JASBIR (20)· patent assignee history
2012–2018Patents assigned to KNOPF JOHN (13)· patent assignee history
2019Based in Cambridge, MA, US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| ACCELERON PHARMA INC | 61 | 2009–2020 |
| KUMAR RAVINDRAself | 30 | 2010–2018 |
| SEEHRA JASBIR | 20 | 2011–2018 |
| KNOPF JOHN | 13 | 2012–2018 |
| GENETICS INST | 7 | 1998–2001 |
Locations
| Location | Patents | Span |
|---|---|---|
| Acton, Massachusetts, US | 63 | 2006–2020 |
| Belmont, Massachusetts, US | 11 | 1998–2012 |
| Bangalore, IN | 6 | 2009–2013 |
| Cambridge, Massachusetts, US | 2 | 2019 |
| Houston, Texas, US | 2 | 2010–2011 |